Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-0

Date publication

novembre 2025

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr MANSI Laura , Dr JOUANNAUD Christelle

Tous les auteurs :
Trédan O, Loirat D, Chabaud S, Toussaint P, Petit T, Viret F, Levy C, Robert A, Grenier J, Mansi L, Spano JP, Patsouris A, Derbel O, Jouannaud C, Ferrero JM, Frenel JS, Molin Y, Doublet L, Heudel PE, Pierga JY, Garin G, Pérol D, Bachelot T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41314029

Résumé

Triple negative breast cancer (TNBC) patients with residual disease after neoadjuvant chemotherapy (NAC) face high risk of recurrence. BREASTIMMUNE-03 trial evaluates the efficacy of nivolumab and ipilimumab combination compared to capecitabine as adjuvant treatment.

Mots clés

Capecitabine, Immune checkpoint inhibitors, Immunotherapy, Ipilimumab, Nivolumab, Residual disease, TNBC

Référence

Breast. 2025 11 21;85:104648